AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Neurosciencenews

Published November 11, 2026

Study Tracks 3, 000 Real-World Psychedelic Journeys - Neuroscience News

Read the full story at Neurosciencenews

UCSF launches CANOPY, an ARPA-H funded study led by Robin Carhart-Harris tracking 3000 real-world psychedelic users with brain imaging and.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelics